Digital Biomarkers & Pathology Congress08 - 11 February 2021 | Manchester, UK

Taking place on Day Three

To accelerate drug development and clinical uptake by bringing together discovery, diagnostics and clinical development collaborators, directors and leaders from Pharma, biotech and healthcare institutions working in this field.

The Congress includes...

Over 100 digital biomarkers and digital pathology attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic and healthcare institutions

Over 20 presentations and case studies focused on the implementation of digital biomarkers and digital pathology

PLUS interactive opportunities including:

  • Interactive panel discussions on Accelerating Digital Pathology and Multiplex Spatial Tissue Analysis
  • Panel discussions on the best strategies in Choosing Digital Endpoints in Clinical Trials & Accelerating Computational Pathology

Agenda at a Glance

  • Clinical Utility and Emerging Applications in Drug Development
  • Choosing Digital Endpoints In Clinical Trials
  • Emerging Applications For Digital Biomarkers
  • Panel Discussion: Choosing Digital Endpoints in Clinical Trials
    • The clinical evidence required for using digital biomarkers as clinical outcome measure in clinical trials
    • The value proposition for digital endpoints
    • The ways to progress digital endpoints beyond the exploratory phase
    • Validation of digital biomarkers
    • Developing digital biomarkers for regulatory acceptance
    • The challenges and opportunities for using wearables, biosensors and smartphones in clinical development
    • Data Analysis Challenges
  • Technology Advances in Biosensors, Wearables and mHealth for Clinical Applications
  • Digital Pathology in Immuno-oncology and Oncology Biomarker Development
  • Digital Pathology and Multiplex Spatial Tissue Analysis
  • Digital Pathology And Image Analysis In Tissue Biomarker Research
  • Artificial Intelligence In Digital Pathology: A Roadmap To Routine Use In Clinical Practice
  • Case studies for Healthcare and Pharma: Bridging the gaps between research, development, and clinical uptake
  • Panel Discussion: Accelerating Computational Pathology
    • Computational pathology and leveraging on big data and artificial intelligence
    • Bridging the gaps between research, development, and clinical uptake
  • Digital Pathology and AI For Precision Medicine
  • Integrating Digital Pathology with Omics Technologies
  • Lisa A Shipley, Vice President Global Digital Analytics & Technologies, Merck
  • Igor Rudychev, Head, Digital, Data & Innovations, Global Commercial Innovation, Digital & Data, Oncology Business Unit, AstraZeneca
  • David Weston, Strategy & Innovation Lead, Emerging Innovations Unit, Discovery Sciences, Astra Zeneca
  • Katharine Locke, Astra Zeneca
  • Francesca Trapani, Resident Molecular Pathology Laboratory Head Dept. of Oncology Translational Science, Boehringer Ingelheim RCV GmbH & Co KG
  • Paul Strijbos, Neurotech Innovation Leader, Product Development Neuroscience Innovation, Hoffmann-La Roche Ltd
  • Mark Milton-Edwards, Head of Product & Health Solutions – Digital Health, Teva
  • Jelena Curcic, Data Scientist, Novartis
  • Laura Kemppainen, Digital Innovation Lead, Roche Finland
  • Laura Parkkinen, Associate Professor, Nuffield Department of Clinical Neurosciences, University of Oxford
  • Charles Massin, Digital Biomarker Product Owner, Roche
  • Vanessa Schumacher, Head of Digital Pathology and Tissue Technologies, Roche
  • Samit Shah, Director Digital Development, NHS
  • Carol Routledge, Digital Biomarkers of Preclinical, Alzheimer’s Research UK
  • Matt Humphries, Scientific Lead (Tissue Hybridisation & Digital Pathology) Precision Medicine Centre of Excellence – Queen’s University Belfast, Centre for Cancer Research and Cell Biology